I think this is a key passage in the piece: "The new product lines we are developing, Dharmanol™ and T-Hydrocan™, are meant to 'upgrade' the YAK capsule model to be more in line with the nutraceutical / pharmaceutical market, as opposed to the more casual approach (...) Because we have the YAK Capsules available in hundreds of California dispensaries, we feel that we can take our time somewhat in perfecting our new offerings, because the market for them is being fulfilled with the YAK capsules currently, which generate substantial ongoing revenues, and have done so for about six years."